Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, S.-Y.
Right arrow Articles by Ishioka, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, S.-Y.
Right arrow Articles by Ishioka, C.
[Cancer Research 60, 3147-3151, June 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Functional Evaluation of PTEN Missense Mutations Using in Vitro Phosphoinositide Phosphatase Assay1

Shuang-Yin Han, Hideaki Kato, Shunsuke Kato, Takao Suzuki, Hiroyuki Shibata, Seiichi Ishii, Ken-ichi Shiiba, Seiki Matsuno, Ryunosuke Kanamaru and Chikashi Ishioka2

Department of Clinical Oncology, Institute of Development, Aging and Cancer [S-Y. H., H. K., S. K., T. S., H. S., R. K., C. I.] and First Department of Surgery, School of Medicine [S-Y. H., S. I., K-i. S., S. M.], Tohoku University, Sendai 980-8575, Japan, and Henan Provincial People’s Hospital, Zhengzhou 450003, China [S-Y. H.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The tumor suppressor gene PTEN is frequently mutated in diverse human cancers and in autosomal dominant cancer predisposition disorders. Recent studies have shown that the lipid phosphatase activity of PTEN is critical for its tumor suppressor function and that PTEN negatively regulates the phosphatidylinositol 3'-kinase-protein kinase B pathway. Although more than half of PTEN mutations result in protein truncation, a significant fraction of PTEN mutations are missense mutations. To examine whether tumor-derived and germ-line-derived missense mutations inactivate PTEN lipid phosphatase function, we constructed 42 distinct types of PTEN missense mutations and expressed them in Escherichia coli. The purified (His)6-tagged PTEN proteins were tested for their ability to dephosphorylate inositol 1,3,4,5-tetrakisphosphate and phosphatidylinositol 3,4,5-triphosphate. In addition, we examined the effect of mutant PTENs on the ability of PTEN to bind to the phospholipid membrane. The results revealed that the majority of PTEN missense mutations [38 of 42 (90%)] eliminated or reduced phosphatase activity and that all of the mutations examined had no effect on the membrane binding activity of PTEN. Our study indicated that phosphoinositide phosphatase activity is important for the tumor suppressor function of PTEN and that there may be other mechanisms of PTEN inactivation that are not monitored by in vitro phosphatase assay and in vitro membrane binding assay.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
The PTEN/MMAC1/TEP1 gene (referred to hereafter as PTEN) was identified recently as a putative tumor suppressor gene located on human chromosome 10q23.3 (1, 2, 3) . Somatic deletions or small mutations of PTEN have been observed with high frequency in malignant glioma (4 , 5) and endometrial cancer (6 , 7) and at a lower rate in other malignancies such as prostate cancer (8) , small cell lung cancer (9) , melanoma (10) , hepatocellular carcinoma (11) , and breast cancer (12) . Germ-line mutations of PTEN have been detected frequently (~80%) in the autosomal dominant hamartoma cancer syndromes Cowden disease (OMIM158350), Bannayan-Zonana syndrome (OMIM153480), and Lhermitte-Duclos disease (13 , 14) . In a murine model, heterozygous knockout mice develop tumors in multiple organs, whereas homozygous deletion of PTEN is embryonically lethal (15 , 16) . Furthermore, enforced expression of PTEN cDNA inhibits cell migration and spreading (17 , 18) and suppresses tumor cell growth by arresting the cell cycle at G1 phase and/or by inducing apoptosis (19) . This genetic and biological evidence suggests that PTEN has an important function in tumorigenesis as well as in normal embryonic development.

The PTEN gene contains nine exons and encodes a 403-amino acid cytoplasmic protein showing extensive NH2-terminal homology with tensin and auxillin as well as having a central catalytic domain showing perfect homology with PTP3 and dual-specific phosphatases (1, 2, 3) . A key step in understanding the function of PTEN as a tumor suppressor is to identify its physiological substrates. Data thus far suggest that PTEN possesses two distinct phosphatase activities. One is a phosphoinositide phosphatase activity against phosphoinositides, such as Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3, which involves dephosphorylation of the D3-position phosphate of the inositol ring (20) . The other is protein phosphatase activity, including focal adhesion kinase (21) . Several studies have shown that the phosphoinositide phosphatase activity of PTEN is critical for its tumor suppressor function, whereas activity toward the protein substrate is not essential for growth suppression (18 , 22, 23, 24, 25) . This suggests that the former activity may play a more important role in tumor suppression by PTEN. Because PtdIns(3,4,5)P3 is a phospholipid second messenger produced by PI3K, PTEN seems to be involved in the PI3K signaling pathway (26) . One of the important downstream targets of PI3K is protein kinase B/Akt, which controls cell proliferation and protects cells from apoptosis (27) . The fact that both PI3K and Akt play critical roles in a variety of growth factor signaling pathways raises the possibility that PTEN functions as a tumor suppressor through negative regulation of the PI3K/Akt pathway.

Loss of PTEN function can occur through homozygous gene deletion, point mutation plus loss of the remaining allele, or loss of expression (1 , 2 , 4 , 28) . We reviewed both somatic and germ-line PTEN mutations by surveying a database of the published literature. There were about 417 mutations reported by the end of August 1999. Among them, 143 (34%) were missense mutations including 90 distinct types, 162 (39%) were frameshift mutations, 73 (18%) were nonsense mutations, and 39 (9%) were other mutations containing in-frame deletion/insertion or splicing site mutations. The frequency of missense mutations in the PTEN gene was higher than that in other tumor suppressor genes except for the p53 gene, which had the highest frequency of missense mutations (~90%). Although both truncating and missense PTEN mutations were scattered throughout the nine exons of PTEN, the missense mutations tended to cluster around the phosphatase domain. In fact, several studies showed that a limited number of reported missense mutations within the phosphatase domain could abrogate the protein phosphatase and/or phosphoinositide phosphatase activity of PTEN (22 , 25) . Even so, the majority of missense mutations, including mutations outside the phosphatase domain, remain to be analyzed. In general, analyses of the effects of missense mutations derived from a disease on the functional properties of the gene product are advantageous to elucidate the most important function for pathogenesis. Therefore, we evaluated the pathogenic effect of a series of PTEN missense mutations.

In this study, we constructed 42 distinct missense mutations that mapped within the PTEN open reading frame and examined the phosphoinositide phosphatase activity of the (His)6-tagged PTEN protein corresponding to each point mutation against Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 as well as their ability to bind a phospholipid membrane in vitro.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Vector Construction and Cloning of Mutant PTEN Alleles.
The wild-type histidine-tagged PTEN [(His)6-PTEN] expression vector was constructed as follows. The full-length open reading frame of PTEN cDNA was amplified by PCR using Pfu DNA polymerase (Stratagene, La Jolla, CA) and a pair of primers with BamHI and HindIII sites. The restriction endonuclease-treated PCR product was inserted into the BamHI/HindIII sites of the pQE30 vector (Qiagen, Hilden, Germany). PTEN cDNA with missense mutations (S10N, Y16C, G20E, Y27S, L42R, H61R, Y68H, C71Y, H93Y, C105F, D107Y, L112P, L112R, A121P, C124R, G129R, G129E, R130G, R130L, R130Q, V133I, M134L, C136Y, Y155C, G165R, S170N, S170R, R173C, R173H, R173P, Y174N, S227F, G251C, K289E, D331G, F341V, K342N, V343E, L345Q, F347L, V369G, and T401I) was constructed by megaprimer PCR (29) . The BamHI/HindIII fragment of mutant PTEN cDNA was introduced into the BamHI/HindIII site of the pQE30 vector to generate mutant (His)6-PTEN expression vectors. All of the plasmids were sequenced to confirm that the appropriate mutation had been incorporated and that no additional mutations were present. These vectors are identical to the wild-type (His)6-PTEN expression vector except for the specific mutations.

Bacterial Expression and Purification of PTEN.
To induce the expression of (His)6-PTEN, the vector was transformed into Escherichia coli strain M15 harboring pREP4 (Qiagen). The resulting transformant was cultured in 50 ml of Luria-Bertani medium at 37°C by mid-log phase (A600 nm = 0.6). Isopropyl ß-D-thiogalactopyranoside was added at a concentration of 0.2 mM, and the culture was incubated for an additional 6 h at 25°C. Thereafter, all of the procedures were performed at 4°C. The bacterial cells were harvested by centrifugation, and the bacterial pellet was frozen at -80°C until use. The frozen pellets were resuspended in 1 ml of ice-cold lysis buffer containing 50 mM NaH2PO4 (pH 8.0), 500 mM NaCl, 5 mM imidazole, 5 mM 2-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride, and bacteriolysis was performed by sonication until the cell suspension became transparent. After the addition of 10 µl of Tween 20, the lysate was incubated on ice for 30 min and then centrifuged at 15,000 x g for 20 min. The supernatant was mixed with 50 µl of Ni-NTA-agarose (Qiagen) for 30 min at 4°C; washed three times with 250 µl of the wash buffer containing 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, and 20 mM imidazole; and eluted three times with 50 µl of the elution buffer containing 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, and 250 mM imidazole. The buffer of the eluted solution was then replaced with 500 µl of TED buffer containing 20 mM Tris-HCl (pH 8.0), 2 mM EDTA, 2 mM DTT, 300 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride by using Nanosep (Pall Filtron, Northborough, MA) and centrifuged to a volume of 50 µl. The purified protein was stored in the presence of 2% (v/v) glycerin at -80°C until use. Protein concentrations and the integrity of fusion proteins were determined by SDS-PAGE and by comparison with known concentrations of BSA.

Ins(1,3,4,5)P4 Phosphatase Assay.
The inositol phosphatase assay was performed using the method described by Maehama and Dixon (20) in a 20-µl reaction volume consisting of 100 mM Tris-HCl (pH 8.0), 10 mM DTT, 60 µM [3H]Ins(1,3,4,5)P4 (0.01 µCi; New England Nuclear, Boston, MA), and 1 µg of the purified (His)6-PTEN protein at 37°C for 30 min. The reaction was terminated by the addition of 1 ml of stop solution consisting of 0.1 M HCOOH and 0.6 M HCOONH4. To separate the dephosphorylated product [3H]Ins(1,4,5)P3 from the substrate, the reaction sample was applied to a AG1-X8 column (0.5 ml; Bio-Rad, Hercules, CA), equilibrated with the stop solution, and eluted with 5 ml of the stop solution. Radioactivity in the eluted solution was measured using a liquid scintillation counter.

PtdIns(3,4,5)P3 Phosphatase Assay.
The (His)6-PTEN protein used for the PtdIns(3,4,5)P3 phosphatase assay was extracted again as described above, except that NaH2PO4 was replaced with 50 mM Tris-HCl (pH 8.0) in the buffer used for lysis, washing, and elution. The phosphatase assays (30) were performed in 50 µl of reaction buffer containing 100 mM Tris-HCl (pH 8.0), 10 mM DTT, 200 µM water-soluble DiC8-PtdIns(3,4,5)P3 (Echelon, Salt Lake City, UT), and 2 µg of (His)6-PTEN protein at 37°C for 40 min. The phosphate released from the substrate was measured using Green Reagent (Biomol, Plymouth Meeting, PA) according to the manufacturer’s instructions. In brief, 500 µl of Green Reagent were added, followed by incubation for 20 min at room temperature. The concentration of the released phosphate was determined by measuring the A620 nm. A standard curve was generated in each assay, and the amount of free phosphate was calculated from the standard curve line-fit data.

Phospholipid Binding Assay.
The PTEN protein binding to LMVs consisting of three different phosphoglycerides, PS, PE, and PC (Sigma, St. Louis, MO), was carried out according to the procedures published previously (31, 32, 33) , with some modifications. Briefly, 100 mg of LMVs (PS:PE:PC ratio, 35:50:15) were prepared in 10 ml of buffer containing 50 mM HEPES-KOH (pH 7.2) and 100 mM NaCl by sonication and collected by centrifugation. An aliquot of (His)6-PTEN protein (2–5 µg) and 100 µl of LMVs were incubated in 50 mM HEPES-KOH (pH 7.2) and 2 mM CaCl2 for 15 min at 25°C. After centrifugation at 12,000 x g for 10 min at 4°C, the pellets containing lipid and bound proteins were washed in 500 µl of the above-mentioned buffer and dissolved in SDS sample buffer. The addition of an equal volume of 20% (w/v) trichloroacetic acid precipitated the proteins in the supernatants. After a 15-min incubation on ice, the samples were centrifuged at 12,000 x g for 15 min at 4°C, washed twice with acetone, and mixed with SDS sample buffer. Equal proportions of the supernatants and pellets were analyzed by 10% (w/v) SDS-PAGE followed by silver staining (Daiichi Pure Chemicals, Tokyo, Japan).


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
To examine whether the missense mutation inactivates the phosphoinositide phosphatase function of PTEN, we selected 42 distinct tumor-derived or germ-line-derived missense mutations covering more than 40% of the reported missense mutation types. Each mutation was constructed by site-directed mutagenesis, expressed as a (His)6-tagged fusion protein [(His)6-PTEN] in E. coli, and purified as described in "Materials and Methods." The amount of expressed (His)6-PTEN was measured by spectrophotometer and confirmed by SDS-PAGE. The representative data are shown in Fig. 1Citation . To assess phosphoinositide phosphatase activity, we used two phosphoinositide substrates with [PtdIns(3,4,5)P3] or without [Ins(1,3,4,5)P4] a diacylglycerol chain. Bacterially expressed PTEN has been shown to dephosphorylate the phosphate in the D3 position of the inositol ring in each substrate (20 , 30 , 33) .



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 1. Bacterial expression and purification of PTEN. Recombinant (His)6-PTEN expressed from wild-type PTEN, null pQE30 vector, and mutant PTEN (Y68H, S170N, G251C, K289E, D331G, and L345Q) in E. coli was purified using Ni-NTA-agarose, as described in "Materials and Methods." Approximately 0.5–1 µg of the proteins was separated by SDS-PAGE and visualized by Coomassie Blue staining. BSA was used for judging the concentration of the PTEN protein. Null, null pQE30 vector as a negative control; PTEN, wild-type PTEN as a positive control.

 
Phosphatase Activities of PTEN against Ins(1,3,4,5)P4.
To examine whether the missense mutations inactivate normal PTEN phosphatase activity against Ins(1,3,4,5)P4, (His)6-PTEN harboring the indicated amino acid substitutions was assayed for its ability to dephosphorylate the phosphate in the D3 position of Ins(1,3,4,5)P4 using the method described previously (Ref. 20 ; Fig. 2Citation ). The results showed that four mutant PTENs (9%; S10N, L42R, V369G, and T401I) retained activity comparable with or even higher than that of normal PTEN, and seven mutant PTENs (17%; G20E, M134L, S227F, K289E, D331G, K342N, and F347L) retained partial activity (Fig. 2Citation ). The remaining 31 mutant PTENs (74%) had no activity.



View larger version (35K):
[in this window]
[in a new window]
  		Fig. 2. Phosphatase activity of PTEN against Ins(1,3,4,5)P4. One µg of (His)6-PTEN protein was assayed for phosphoinositol phosphatase activity against [3H]Ins(1,3,4,5)P4 as described in "Materials and Methods." The radioactivity of the dephosphorylated product was counted, and the results were normalized to wild-type PTEN (100%). The 42 PTEN mutants were divided into seven groups (A-G) for protein extraction and phosphatase assay. The data are representative of three independent experiments that yielded similar results.

 
Phosphatase Activities of PTEN against PtdIns(3,4,5)P3.
Because Ins(1,3,4,5)P4 lacks the diacylglycerol chain of PtdIns(3,4,5)P3, we compared the phosphoinositide phosphatase activities of 12 selected mutant PTENs and normal PTEN toward the two substrates. These PTENs contained mutants with full (S10N, L42R, V369G, and T401I), partial (G20E, M134L, S227F, and K342N), and no (Y68H, G129E, R130G, and R173C) phosphatase activities against Ins(1,3,4,5)P4. Water-soluble PtdIns(3,4,5)P3 was used to examine the released phosphate. The eight mutant PTENs with full or partial Ins(1,3,4,5)P4 phosphatase activity showed nearly the same level of phosphatase activity against PtdIns(3,4,5)P3 as wild-type PTEN, whereas the four mutant PTENs with no Ins(1,3,4,5)P4 phosphatase activity also eliminated PtdIns(3,4,5)P3 phosphatase activity (Fig. 3Citation ). These results indicated that the effects of the missense mutations on PTEN phosphatase activity against the two phosphoinositides were nearly identical, although the assay using Ins(1,3,4,5)P4 may be more sensitive to subtle structural changes in PTEN than that using PtdIns(3,4,5)P3.



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 3. Phosphatase activity of PTEN against PtdIns(3,4,5) P3. Two µg of (His)6-PTEN were assayed for phosphoinositol phosphatase activity against water-soluble diC8-PtdIns(3,4,5)P3. The amount of free phosphate released in the reaction was measured at A620 nm and compared with a standard curve. The data are representative of three experiments that yielded similar results.

 
Ability of PTEN to Bind to LMVs.
During our study of PTEN phosphatase activities, a second biochemical property of PTEN was reported: the ability to bind to lipid membranes in vitro through the C2 domain (33) . This raised the possibility that some PTEN mutations may inactivate the physiological function of PTEN through disruption of the membrane binding activity. To examine this possibility, 15 mutant PTENs with (S10N, L42R, K289E, D331G, V369G, and T401I) or without (Y16C, Y68H, R130Q, R130L, G165R, S170N, R173C, G251C, and L345Q) phosphatase activity were subjected to a protein-membrane binding assay using LMVs that consisted of three different phosphoglycerides (PC, PS, and PE) according to procedures published previously (31 , 32) . Representative data of the selected mutant PTENs are shown in Fig. 4Citation . When bacterial proteins copurified with PTEN failed to bind LMVs, all mutants tested retained the binding activity of PTEN, irrespective of whether or not they had phosphoinositide phosphatase activity. This result suggested that the ability of PTEN to bind to membranes is not a major target of tumor-derived or germ-line-derived missense mutations, even if the activity may be important for physiological PTEN function.



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 4. PTEN binding activity to LMVs. A representative silver-stained gel of protein bound to LMVs is shown. P, the pellet fraction coprecipitated with LMVs. S, the supernatant fraction without binding to LMVs. Note that proteins other than PTENs exist only in the supernatant fractions.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Since its discovery, PTEN has been thought to be a protein phosphatase because it shares the signature motif HCXXGXXR with the active site of PTPs and dual-specific protein phosphatases. However, recent studies have shown that the biologically relevant targets of PTEN may not be phosphoproteins but rather a subset of phosphoinositides (20 , 22 , 25) . This speculation can be supported by several findings. For example, tumor cell lines with mutant PTEN retained elevated levels of PtdIns(3,4,5)P3 and Akt activity, and the introduction of wild-type PTEN reduced the levels of both (34 , 35) . Furthermore, analysis of the PTEN crystal structure indicated that the phosphatase active site of PTEN is larger than that of the PTPs and that the COOH-terminal portion has a structure similar to the C2 domain and actually binds to phospholipid membranes in vitro (33) . To elucidate the most important tumor suppressor function of PTEN, the analysis of the effect of the missense mutations on currently known functional properties of PTEN will be beneficial until all of the functions of PTEN are clarified. Thus far, only a limited number of tumor-derived and germ-line-derived PTEN missense mutations have been examined for known PTEN functions. All of the missense mutations that have been tested inactivated phosphoinositide phosphatase activity, whereas some of the mutations retained protein phosphatase activity (22 , 25) . Although these observations stressed the importance of phosphoinositide phosphatase activity, it was necessary to determine whether the reported PTEN missense mutations inactivate the currently proposed functions of PTEN.

As an initial study, we constructed 42 missense mutations, which covered more than 40% of reported missense mutations, mapped throughout from the NH2-terminal and COOH-terminal portions of PTEN and tested them against the phosphoinositide phosphatase activity and membrane binding activity of wild-type PTEN. We classified them according to the recent report describing PTEN crystal structure (33) . There were 31 mutations (S10N, Y16C, G20E, Y27S, L42R, H61R, Y68H, C71Y, H93Y, C105F, D107Y, L112P, L112R, A121P, C124R, G129R, G129E, R130G, R130L, R130Q, V133I, M134L, C136Y, Y155C, G165R, S170N, S170R, R173C, R173H, R173P, and Y174N) within the NH2-terminal phosphatase domain (residues 7–185), 9 mutations (S227F, G251C, K289E, D331G, F341V, K342N, V343E, L345Q, and F347L) within the COOH-terminal C2 domain (residues 186–351), and 2 mutations (V369G and T401I) close to the COOH-terminal end. Among these mutations, most of the mutations within the NH2-terminal phosphatase domain (27 of 31 mutations, 87%) inactivated phosphatase activity. In contrast, a higher percentage of mutations within both the C2 domain (five of nine mutations, 56%) and the COOH-terminal end (two of two mutations, 100%) retained phosphatase activity. Overall, our results showed that most mutations (38 of 42 mutations, 90%) eliminated or reduced phosphatase activity. The mutations within the phosphatase domain contain eight mutations located at the predicted active site pocket, including six mutations (C124R, G129R, G129E, R130G, R130L, and R130Q) in the HCXXGRXXR signature motif of the P loop (residues 123–130) at the bottom of the pocket and two mutations (H93Y and G165R) at the walls of the pocket, the WPD loop (residues 90–97), and the TI loop (residues 160–168), respectively. All mutations within the active site pocket eliminated phosphatase activity. The mutations in the motif represent 19% (27 of 143) of the total missense mutations according to our statistics. From our functional analysis and the previous genetic and structural analyses, we conclude that PTEN phosphoinositide phosphatase activity is an important tumor-suppressive function of PTEN.

However, 26% (11 of 42) of the mutants retained some level of the normal PTEN phosphatase activity in vitro. Although there may be a polymorphism(s) among these mutants, it is likely that the in vitro phosphatase assays do not always reflect the in vivo phosphatase activity of PTEN and that there might be other mechanisms of PTEN inactivation. In our study, most of the mutations that mapped to the COOH-terminal region retained some levels of phosphoinositide phosphatase activity. According to recent studies, there may be regulatory domains in the COOH-terminal region. Georgescu et al. (30) have shown that two missense mutations (L345Q and T348I) in the predicted ß-strand structure (residues 342–349) seem to destabilize PTEN in mammalian cells, although these mutations are also defective in the phosphatase assay by bacterially expressed proteins. Lee et al. (33) have shown that the predicted C2 domain in the COOH-terminal portion bound to phospholipid membranes. They also speculated that the C2 and the phosphatase domains associate across an extensive interface adjacent to the phosphatase active site. Furthermore, they predicted that the C2 domain may not only recruit PTEN to the membrane but may also help with the positioning and orientation of the catalytic domain with respect to the membrane-bound substrate. In this study, we could not find any tumor-derived mutations that affected the membrane binding activity of PTEN, which suggested that the binding of PTEN to membranes is not a major target of the missense mutations. Our results do not exclude the possibility of binding activity as an important tumor suppressor function of PTEN because there are high frequencies of PTEN frameshift (39%) and nonsense (18%) mutations that are predicted to eliminate the PTEN membrane binding domain and perhaps preserve enzyme activity. It would be of great interest to determine whether the mutations in the C2 domain, which have both in vitro phosphatase and membrane binding activities, affect the phosphatase activity under the conditions of PTEN protein binding to the phospholipid membrane.

PTEN also has another domain, called the PDZ binding domain, in the COOH-terminal end (33 , 36) ; the domain binds to the PDZ proteins (DLG1 and MAST205), and this binding is regulated by phosphorylation of the tyrosine residue at codon 401. It would also be interesting to determine whether tumor-derived T401I mutations with in vitro phosphatase activity inactivate binding to the PDZ proteins.

Finally, we found that some mutants with partial phosphatase activity against Ins(1,3,4,5)P4 (G20E, M134L, S227F, and K342N) showed nearly wild-type levels of phosphatase activity against PtdIns(3,4,5)P3. It is possible that certain PTEN mutations impair phosphatase activity only toward one type of inositol phosphate molecule [Ins(1,3,4,5)P4] but not others [i.e., PtdIns(3,4,5)P3] and therefore affect distinct cellular signaling pathways because these two molecules have different functions in the cell: Ins(1,3,4,5)P4 is a second messenger involved in regulating intracellular calcium signaling, whereas PtdIns(3,4,5)P3 is well known as a second messenger molecule generated by PI3K activity (20) . Taken together, PTEN phosphatase activity could be regulated by subcellular location, phosphorylation, and/or interaction with other cellular proteins. The physiological function of PTEN remains to be clarified in additional experiments.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by grants-in-aid from the Ministry of Education, Science, Sports and Culture and the Ministry of Health and Welfare, Japan. Back

2 To whom requests for reprints should be addressed, at Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Phone: 81-22-717-8547; Fax: 81-22-717-8548; E-mail: chikashi{at}idac.tohoku.ac.jp Back

3 The abbreviations used are: PTP, protein tyrosine phosphatase; Ins(1,3,4,5)P4, inositol 1,3,4,5-tetrakisphosphate; PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-triphosphate; PI3K, phosphatidylinositol 3'-kinase; LMV, large multilamellar vesicle; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine. Back

Received 3/ 1/00. Accepted 5/ 4/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.[Abstract/Free Full Text]
  2. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. H., Tavtigian S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.[Medline]
  3. Li D. M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor ß. Cancer Res., 57: 2124-2129, 1997.[Abstract/Free Full Text]
  4. Maier D., Zhang Z., Taylor E., Hamou M. F., Gratzl O., Van Meir E. G., Scott R. J., Merlo A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25–26 region as the primary target in low-grade and high-grade gliomas. Oncogene, 16: 3331-3335, 1998.[Medline]
  5. Duerr E. M., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D. N., Schramm J., Wiestler O. D., Parsons R., Eng C., von Deimling A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 16: 2259-2264, 1998.[Medline]
  6. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res., 57: 3935-3940, 1997.[Abstract/Free Full Text]
  7. Obata K., Morland S. J., Watson R. H., Hitchcock A., Chenevix-Trench G., Thomas E. J., Campbell I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58: 2095-2097, 1998.[Abstract/Free Full Text]
  8. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res., 57: 4997-5000, 1997.[Abstract/Free Full Text]
  9. Forgacs E., Biesterveld E. J., Sekido Y., Fong K., Muneer S., Wistuba I. I., Milchgrub S., Brezinschek R., Virmani A., Gazdar A. F., Minna J. D. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 17: 1557-1565, 1998.[Medline]
  10. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res., 57: 3660-3663, 1997.[Abstract/Free Full Text]
  11. Yao Y. J., Ping X. L., Zhang H., Chen F. F., Lee P. K., Ahsan H., Chen C. J., Lee P. H., Peacocke M., Santella R. M., Tsou H. C. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene, 18: 3181-3185, 1999.[Medline]
  12. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res., 57: 3657-3659, 1997.[Abstract/Free Full Text]
  13. Nelen M. R., van Staveren W. C., Peeters E. A., Hassel M. B., Gorlin R. J., Hamm H., Lindboe C. F., Fryns J. P., Sijmons R. H., Woods D. G., Mariman E. C., Padberg G. W., Kremer H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet., 6: 1383-1387, 1997.[Abstract/Free Full Text]
  14. Marsh D. J., Coulon V., Lunetta K. L., Rocca-Serra P., Dahia P. L., Zheng Z., Liaw D., Caron S., Duboue B., Lin A. Y., Richardson A. L., Bonnetblanc J. M., Bressieux J. M., Cabarrot-Moreau A., Chompret A., Demange L., Eeles R. A., Yahanda A. M., Fearon E. R., Fricker J. P., Gorlin R. J., Hodgson S. V., Huson S., Lacombe D., Eng C., et al Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet., 7: 507-515, 1998.[Abstract/Free Full Text]
  15. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet., 19: 348-355, 1998.[Medline]
  16. Suzuki A., de la Pompa J. L., Stambolic V., Elia A. J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., Mak T. W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol., 8: 1169-1178, 1998.[Medline]
  17. Furnari F. B., Lin H., Huang H. S., Cavenee W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA, 94: 12479-12484, 1997.[Abstract/Free Full Text]
  18. Tamura M., Gu J., Takino T., Yamada K. M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res., 59: 442-449, 1999.[Abstract/Free Full Text]
  19. Li D. M., Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA, 95: 15406-15411, 1998.[Abstract/Free Full Text]
  20. Maehama T., Dixon J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273: 13375-13378, 1998.[Abstract/Free Full Text]
  21. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K. M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (Washington DC), 280: 1614-1617, 1998.[Abstract/Free Full Text]
  22. Myers M. P., Pass I., Batty I. H., Van der Kaay J., Stolarov J. P., Hemmings B. A., Wigler M. H., Downes C. P., Tonks N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA, 95: 13513-13518, 1998.[Abstract/Free Full Text]
  23. Sun H., Lesche R., Li D. M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA, 96: 6199-6204, 1999.[Abstract/Free Full Text]
  24. Wu X., Senechal K., Neshat M. S., Whang Y. E., Sawyers C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA, 95: 15587-15591, 1998.[Abstract/Free Full Text]
  25. Furnari F. B., Huang H. J., Cavenee W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res., 58: 5002-5008, 1998.[Abstract/Free Full Text]
  26. Cantley L. C., Neel B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA, 96: 4240-4245, 1999.[Abstract/Free Full Text]
  27. Franke T. F., Yang S. I., Chan T. O., Datta K., Kazlauskas A., Morrison D. K., Kaplan D. R., Tsichlis P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81: 727-736, 1995.[Medline]
  28. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA, 95: 5246-5250, 1998.[Abstract/Free Full Text]
  29. Upender, M., Raj, L., and Weir, M. Megaprimer method for in vitro mutagenesis using parallel templates. Biotechniques, 18: 29–30, 32, 1995.
  30. Georgescu M. M., Kirsch K. H., Akagi T., Shishido T., Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. USA, 96: 10182-10187, 1999.[Abstract/Free Full Text]
  31. Fukuda M., Kojima T., Mikoshiba K. Phospholipid composition dependence of Ca2+-dependent phospholipid binding to the C2A domain of synaptotagmin IV. J. Biol. Chem., 271: 8430-8434, 1996.[Abstract/Free Full Text]
  32. Davletov B., Perisic O., Williams R. L. Calcium-dependent membrane penetration is a hallmark of the C2 domain of cytosolic phospholipase A2, whereas the C2A domain of synaptotagmin bind membranes electrostatically. J. Biol. Chem., 273: 19093-19096, 1998.[Abstract/Free Full Text]
  33. Lee J. O., Yang H., Georgescu M. M., Di Cristofano A., Maehama T., Shi Y., Dixon J. E., Pandolfi P., Pavletich N. P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 99: 323-334, 1999.[Medline]
  34. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.[Medline]
  35. Stambolic V., Suzuki A., de la Pompa J. L., Brothers G. M., Mirtsos C., Sasaki T., Ruland J., Penninger J. M., Siderovski D. P., Mak T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95: 29-39, 1998.[Medline]
  36. Adey N. B., Huang L., Ormonde P. A., Baumgard M. L., Pero R., Byreddy D. V., Tavtigian S. V., Bartel P. L. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res., 60: 35-37, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Andres-Pons, I. Rodriguez-Escudero, A. Gil, A. Blanco, A. Vega, M. Molina, R. Pulido, and V. J. Cid
In vivo Functional Analysis of the Counterbalance of Hyperactive Phosphatidylinositol 3-Kinase p110 Catalytic Oncoproteins by the Tumor Suppressor PTEN
Cancer Res., October 15, 2007; 67(20): 9731 - 9739.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
U. A. Kayisli, M. Berkkanoglu, G. Kizilay, L. Senturk, and A. Arici
Expression of Proliferative and Preapoptotic Molecules in Human Myometrium and Leiomyoma Throughout the Menstrual Cycle
Reproductive Sciences, October 1, 2007; 14(7): 678 - 686.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
O. Guzeloglu-Kayisli, U. A. Kayisli, R. Al-Rejjal, W. Zheng, G. Luleci, and A. Arici
Regulation of PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10) Expression by Estradiol and Progesterone in Human Endometrium
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5017 - 5026.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
W. Reardon, X.-P. Zhou, and C. Eng
A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association
J. Med. Genet., December 1, 2001; 38(12): 820 - 823.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, S.-Y.
Right arrow Articles by Ishioka, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, S.-Y.
Right arrow Articles by Ishioka, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online